Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells $218,099.34 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $95.91, for a total transaction of $218,099.34. Following the completion of the sale, the chief operating officer now directly owns 69,383 shares in the company, valued at $6,654,523.53. This trade represents a 3.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Christina Rossi also recently made the following trade(s):

• On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.10, for a total transaction of $216,257.40.

Blueprint Medicines Stock Up 1.4 %

Blueprint Medicines stock opened at $90.14 on Monday. The stock has a market cap of $5.73 billion, a PE ratio of -42.72 and a beta of 0.59. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The stock’s fifty day moving average is $92.48 and its two-hundred day moving average is $97.09. Blueprint Medicines Co. has a 1-year low of $72.24 and a 1-year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.08. The business had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business’s quarterly revenue was up 126.5% on a year-over-year basis. During the same quarter last year, the company earned ($2.20) EPS. On average, sell-side analysts expect that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BPMC. JPMorgan Chase & Co. initiated coverage on Blueprint Medicines in a research report on Thursday, November 14th. They set an “overweight” rating and a $126.00 price target for the company. Wells Fargo & Company dropped their target price on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. UBS Group started coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 price target on the stock. Guggenheim reissued a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Finally, Wedbush reaffirmed an “outperform” rating and set a $135.00 target price on shares of Blueprint Medicines in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Blueprint Medicines has an average rating of “Moderate Buy” and a consensus price target of $123.33.

Institutional Trading of Blueprint Medicines

Institutional investors have recently modified their holdings of the stock. Hsbc Holdings PLC acquired a new stake in Blueprint Medicines during the 2nd quarter worth $1,060,000. Federated Hermes Inc. grew its holdings in shares of Blueprint Medicines by 27.8% during the second quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock worth $6,721,000 after purchasing an additional 13,579 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Blueprint Medicines by 48.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock worth $23,332,000 after purchasing an additional 82,693 shares in the last quarter. Nicholas Investment Partners LP purchased a new stake in shares of Blueprint Medicines in the 2nd quarter valued at about $4,377,000. Finally, Entropy Technologies LP acquired a new stake in shares of Blueprint Medicines in the 3rd quarter valued at about $999,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.